Antiplatelet Therapy in Patients at Risk of Bleeding

Comparative Bleeding Risk Profiles

The European Society of Cardiology recommends using the lowest dose of aspirin that has been shown to be effective in each clinical setting to minimize dose-dependent GI toxicity 1
Low-dose aspirin (75-100 mg) is recommended as the optimal daily dose for long-term prevention in high-risk patients, as it provides effective antithrombotic protection while minimizing gastrointestinal toxicity 1
For patients at risk of bleeding, low-dose aspirin (75-100 mg daily) is preferred over clopidogrel due to its more favorable bleeding risk profile when used at the lowest effective dose 1, 2

For patients with acute coronary syndromes, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is recommended, but bleeding risk increases significantly 2, 5
The European Society of Cardiology recommends using clopidogrel alone or dipyridamole plus aspirin for secondary prevention in patients with non-cardioembolic transient ischemic attack or ischemic stroke 2
For patients who cannot tolerate dipyridamole or clopidogrel, aspirin alone is recommended 2

In pediatric patients with systemic-to-pulmonary shunts, low-dose aspirin has been shown to reduce the risk of shunt thrombosis compared to no antiplatelet therapy 6

For long-term prevention in high-risk patients, use aspirin at the lowest effective dose (75-100 mg daily) 1, 2
For patients requiring anticoagulation who are at high bleeding risk, aspirin at 81 mg daily is the recommended maintenance dose when used with newer anticoagulants 7

The combination of aspirin and clopidogrel significantly increases bleeding risk compared to either agent alone 4, 5
When using aspirin with ticagrelor, the recommended maintenance dose is 81 mg daily to minimize bleeding risk 7
Thrombotic thrombocytopenic purpura (TTP) is a rare but serious complication that can occur within 2 weeks of initiating clopidogrel therapy 4